Erythropoietin response and route of administration

J. E. Taylor, J. J. F. Belch, L. W. Fleming, R. A. Mactier, I. S. Henderson, W. K. Stewart

    Research output: Contribution to journalArticle

    55 Citations (Scopus)

    Abstract

    The effect of route of erythropoietin (EPO) administration was assessed in sixteen hemodialysis patients who completed a randomised crossover study of thrice weekly subcutaneous (SC) and intravenous (IV) erythropoietin with an EPO-free washout period separating the two phases of treatment. Route of EPO administration had no significant effect on absolute reticulocyte counts, and change in hemoglobin (Hb) during the first six weeks of therapy, at a constant EPO dose (120 iu/kg/week). Similarly, there was no significant difference in EPO dose requirement between the two routes, both during and after correction of anemia, and after maintenance of target Hb (10-12 g/dl) for an eight-week period (end of maintenance period dose; median [range]; SC EPO: 120 [30-367] iu/kg/week, IV EPO: 124.5 [37-377] iu/kg/week). Following EPO withdrawal, Hb fell at a rate of 0.38 (0.14-0.69) g/dl/week. Route of EPO administration did not influence the incidence of thrombotic and hypertensive side effects, or increases in dialysis heparin requirement and albumin, and decreases in ferritin, alpha-1-antitrypsin and ceruloplasmin during the study period. In conclusion, thrice weekly SC and IV EPO are comparable in terms of efficacy and safety.
    Original languageEnglish
    Pages (from-to)297-302
    Number of pages6
    JournalClinical Nephrology
    Volume41
    Issue number5
    Publication statusPublished - 1994

    Fingerprint

    Erythropoietin
    Hemoglobins
    Maintenance
    Reticulocyte Count
    alpha 1-Antitrypsin
    Ceruloplasmin
    Ferritins
    Cross-Over Studies
    Renal Dialysis
    Heparin
    Anemia
    Dialysis
    Albumins
    Safety

    Cite this

    Taylor, J. E., Belch, J. J. F., Fleming, L. W., Mactier, R. A., Henderson, I. S., & Stewart, W. K. (1994). Erythropoietin response and route of administration. Clinical Nephrology, 41(5), 297-302.
    Taylor, J. E. ; Belch, J. J. F. ; Fleming, L. W. ; Mactier, R. A. ; Henderson, I. S. ; Stewart, W. K. / Erythropoietin response and route of administration. In: Clinical Nephrology. 1994 ; Vol. 41, No. 5. pp. 297-302.
    @article{97ed92abf28e4020b38149125463ad3a,
    title = "Erythropoietin response and route of administration",
    abstract = "The effect of route of erythropoietin (EPO) administration was assessed in sixteen hemodialysis patients who completed a randomised crossover study of thrice weekly subcutaneous (SC) and intravenous (IV) erythropoietin with an EPO-free washout period separating the two phases of treatment. Route of EPO administration had no significant effect on absolute reticulocyte counts, and change in hemoglobin (Hb) during the first six weeks of therapy, at a constant EPO dose (120 iu/kg/week). Similarly, there was no significant difference in EPO dose requirement between the two routes, both during and after correction of anemia, and after maintenance of target Hb (10-12 g/dl) for an eight-week period (end of maintenance period dose; median [range]; SC EPO: 120 [30-367] iu/kg/week, IV EPO: 124.5 [37-377] iu/kg/week). Following EPO withdrawal, Hb fell at a rate of 0.38 (0.14-0.69) g/dl/week. Route of EPO administration did not influence the incidence of thrombotic and hypertensive side effects, or increases in dialysis heparin requirement and albumin, and decreases in ferritin, alpha-1-antitrypsin and ceruloplasmin during the study period. In conclusion, thrice weekly SC and IV EPO are comparable in terms of efficacy and safety.",
    author = "Taylor, {J. E.} and Belch, {J. J. F.} and Fleming, {L. W.} and Mactier, {R. A.} and Henderson, {I. S.} and Stewart, {W. K.}",
    year = "1994",
    language = "English",
    volume = "41",
    pages = "297--302",
    journal = "Clinical Nephrology",
    issn = "0301-0430",
    publisher = "Dustri-Verlag",
    number = "5",

    }

    Taylor, JE, Belch, JJF, Fleming, LW, Mactier, RA, Henderson, IS & Stewart, WK 1994, 'Erythropoietin response and route of administration', Clinical Nephrology, vol. 41, no. 5, pp. 297-302.

    Erythropoietin response and route of administration. / Taylor, J. E.; Belch, J. J. F.; Fleming, L. W.; Mactier, R. A.; Henderson, I. S.; Stewart, W. K.

    In: Clinical Nephrology, Vol. 41, No. 5, 1994, p. 297-302.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Erythropoietin response and route of administration

    AU - Taylor, J. E.

    AU - Belch, J. J. F.

    AU - Fleming, L. W.

    AU - Mactier, R. A.

    AU - Henderson, I. S.

    AU - Stewart, W. K.

    PY - 1994

    Y1 - 1994

    N2 - The effect of route of erythropoietin (EPO) administration was assessed in sixteen hemodialysis patients who completed a randomised crossover study of thrice weekly subcutaneous (SC) and intravenous (IV) erythropoietin with an EPO-free washout period separating the two phases of treatment. Route of EPO administration had no significant effect on absolute reticulocyte counts, and change in hemoglobin (Hb) during the first six weeks of therapy, at a constant EPO dose (120 iu/kg/week). Similarly, there was no significant difference in EPO dose requirement between the two routes, both during and after correction of anemia, and after maintenance of target Hb (10-12 g/dl) for an eight-week period (end of maintenance period dose; median [range]; SC EPO: 120 [30-367] iu/kg/week, IV EPO: 124.5 [37-377] iu/kg/week). Following EPO withdrawal, Hb fell at a rate of 0.38 (0.14-0.69) g/dl/week. Route of EPO administration did not influence the incidence of thrombotic and hypertensive side effects, or increases in dialysis heparin requirement and albumin, and decreases in ferritin, alpha-1-antitrypsin and ceruloplasmin during the study period. In conclusion, thrice weekly SC and IV EPO are comparable in terms of efficacy and safety.

    AB - The effect of route of erythropoietin (EPO) administration was assessed in sixteen hemodialysis patients who completed a randomised crossover study of thrice weekly subcutaneous (SC) and intravenous (IV) erythropoietin with an EPO-free washout period separating the two phases of treatment. Route of EPO administration had no significant effect on absolute reticulocyte counts, and change in hemoglobin (Hb) during the first six weeks of therapy, at a constant EPO dose (120 iu/kg/week). Similarly, there was no significant difference in EPO dose requirement between the two routes, both during and after correction of anemia, and after maintenance of target Hb (10-12 g/dl) for an eight-week period (end of maintenance period dose; median [range]; SC EPO: 120 [30-367] iu/kg/week, IV EPO: 124.5 [37-377] iu/kg/week). Following EPO withdrawal, Hb fell at a rate of 0.38 (0.14-0.69) g/dl/week. Route of EPO administration did not influence the incidence of thrombotic and hypertensive side effects, or increases in dialysis heparin requirement and albumin, and decreases in ferritin, alpha-1-antitrypsin and ceruloplasmin during the study period. In conclusion, thrice weekly SC and IV EPO are comparable in terms of efficacy and safety.

    M3 - Article

    C2 - 8050210

    VL - 41

    SP - 297

    EP - 302

    JO - Clinical Nephrology

    JF - Clinical Nephrology

    SN - 0301-0430

    IS - 5

    ER -

    Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clinical Nephrology. 1994;41(5):297-302.